Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Averna Therapeutics

Request full access

Redosable mRNA genomic medicines platform

Watertown, United StatesFounded 2024Biotech & Life Sciences

About Averna Therapeutics

Averna Therapeutics, formerly known as Exsilio Therapeutics, is a biotechnology company developing genomic medicines that insert therapeutic genetic instructions into safe-harbor sites in the genome. The platform is designed for redosable treatments across genetic diseases, cancer, and autoimmune conditions using RNA delivered in lipid nanoparticles.

Averna engineers naturally occurring genetic elements encoded in messenger RNA so new genes can be inserted precisely into disease-relevant cells. Because the medicines are encoded in mRNA, they can use validated non-viral delivery approaches that support redosing with curative intent. The company targets patients and development partners in genomic medicine who need durable gene insertion without relying solely on one-time viral vectors.

Averna operates as a clinical-stage genomic medicine developer advancing its RNA/LNP insertion platform from research into therapeutic programs. Public materials describe predictive in silico modeling combined with wet-lab engineering of insertion elements, with headquarters in the Greater Boston area.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2024
Headquarters
Watertown, United States
Employees
54
Open positions
None listed
Dealroom signal
54.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SPINOUTOther financing Jun 2024 $0 — Weizmann Institute of Science —
SERIES AOther financing Jun 2024 $82M $328M Innovation Endeavors · Invus · CRISPR Therapeutics · OrbiMed ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Averna Therapeutics website traffic

Latest recorded traffic for Averna Therapeutics is 40 monthly website visits, down 96% over the last three months. Averna Therapeutics's team grew 1.9% over the past year.

Latest monthly visits40 3-month web change-96% 1-year team growth+1.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Averna Therapeutics in the Watertown ecosystem

Live from Dealroom

The Averna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

Other known investors1 additional known investor

  • Weizmann Institute of Science
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇮🇱 Israel58.9%
🇺🇸 United States41.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Averna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Averna Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.